The Effect of Butanediol Ingestion on Skeletal Muscle Angiogenesis in Hypoxia
The Acute Effect of (R)-1,3-butanediol Ingestion on Post-exercise Skeletal Muscle Angiogenesis in Healthy Adults Under Normoxic and Hypoxic Conditions.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Chiel Poffé
- Email: chiel.poffe@kuleuven.be
Study Contact Backup
- Name: Myrthe Stalmans
- Phone Number: 0485440736
- Email: myrthe.stalmans@kuleuven.be
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- KU Leuven
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent must be obtained prior to any experimental procedures
- Biological male or biological females using oral contraception between 18 and 35 years old
- Recreational or competitive cyclists performing regularly cycling training sessions with an average training volume of more than 6 hours per week
- Good health status confirmed by a medical screening
- Body Mass Index (BMI) between 18 and 25 kg/m2
Exclusion Criteria:
- Any kind of injury/pathology that is a contra-indication for hypoxic exposure and/or to perform high-intensity exercise, evaluated by a sport medical screening
- Intake of any medication or nutritional supplement that is known to affect exercise or performance. Intake will be assessed during recruitment and the sport medical screening.
- Intake of analgesics, anti-inflammatory agents, or supplementary anti-oxidants, within two weeks of study participation.
- Recent residence or training under hypoxia; more than 7 days exposure to altitude > 1500 m during the 3 months preceding the study.
- Blood donation within 3 months of study participation.
- Habitual smoking
- Pre-existing, diagnosed psychiatric conditions or anxiety
- Females that are pregnant or are planning to be pregnant before the end of the study (end of May 2024)
- Depression or anxiety as assessed by the Beck Depression Inventory 25 (Appendix 2) and Beck Anxiety Inventory 26 (Appendix 3). Only a score in the range of 'normal ups and downs' (score 1-10) for depression or 'minimal anxiety' (score 0-7) for anxiety are tolerated.
- History of addiction or excessive caffeine/alcohol consumption assessed by a questionnaire (Appendix 4).
- Any other reason that might pose undue risk to the participant, or introduce bias into the study outcomes, at the discretion of the research team.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 1 session with normoxic post-exercise recovery, supplemented with placebo (NPL)
Normoxic training, followed by normoxic recovery with placebo supplements
|
Altitude: sea level Dietary supplement: placebo.
Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
|
|
Experimental: 1 session with normoxic post-exercise recovery, supplemented with ketones (NKE)
Normoxic training, followed by normoxic recovery with ketone supplements
|
Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
|
|
Experimental: 1 session with hypoxic post-exercise recovery, supplemented with placebo (HPL)
Normoxic training, followed by hypoxic (simulated altitude of 3000m) recovery with placebo supplements
|
Altitude: 3,000m (simulated) Dietary supplement: placebo.
Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w
|
|
Experimental: 1 session with hypoxic post-exercise recovery, supplemented with ketones (HKE)
Normoxic training, followed by hypoxic (simulated altitude of 3000m) recovery with ketone supplements
|
Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-exercise muscle VEGF mRNA expression
Time Frame: Muscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.
|
Measured using PCR on collected muscle biopsies
|
Muscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.
|
|
Post-exercise serum EPO concentrations
Time Frame: Venous blood samples are collected 10 minutes after the end of training as well as 3 hours, 5 hours and 7 hours later.
|
Measured using ELISA on collected serum samples
|
Venous blood samples are collected 10 minutes after the end of training as well as 3 hours, 5 hours and 7 hours later.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in muscular VEGF concentration
Time Frame: Muscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.
|
Measured using Western Blotting on muscle biopsies
|
Muscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.
|
|
Change in serum VEGF concentration
Time Frame: Venous blood samples are collected immediately (5 minutes) after the end of training, as well as 3hours, 5hours and 7hours later..
|
Measured using ELISA on collected serum samples
|
Venous blood samples are collected immediately (5 minutes) after the end of training, as well as 3hours, 5hours and 7hours later..
|
|
Change in blood oxygenation
Time Frame: Continuously measured starting 30 minutes after the end of exerciseuntil 7.5 hours later
|
Measured using pulse oximetry with a sensor on the forehead
|
Continuously measured starting 30 minutes after the end of exerciseuntil 7.5 hours later
|
|
Exercise performance
Time Frame: Performed 7hours and 30minutes after the end of training
|
Measured as the average power output (W) during a 15 minutes all-out time trial
|
Performed 7hours and 30minutes after the end of training
|
|
Change in skeletal muscle oxygenation
Time Frame: Measured during resting measurements performed 30 minutes, 3hours and 30minutes as well as 6hours and 30minutes after the end of training.
|
Measured using NIRS with a sensor on the belly of the m.
vastus lateralis (skeletal muscle)
|
Measured during resting measurements performed 30 minutes, 3hours and 30minutes as well as 6hours and 30minutes after the end of training.
|
|
Change in peripheral blood flow
Time Frame: Measured during resting measurements performed 30 minutes, 3hours and 30minutes as well as 6hours and 30minutes after the end of the training
|
Measured using duplex ultrasonography
|
Measured during resting measurements performed 30 minutes, 3hours and 30minutes as well as 6hours and 30minutes after the end of the training
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in citrate synthase as a marker of mitochondrial density
Time Frame: Muscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.
|
Measured using an enzymatic essay
|
Muscle biopsies are collected 10 minutes after the end of training as well as 3 hours later.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chiel Poffé, KU Leuven
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- S68402
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.